In human EGFRm NSCLC tissues relapsed from treatment with EGFR‐TKIs including osimertinib, TRPM2 elevation was detected in 56.5% (13/23) of cases compared with their matched pre‐treatment tissues, whereas TRPM2 expression remained unchanged in 30.4% (7/23) of cases post relapse (Figure 4F,G). This evidence concerns the gene EGFR and non-small cell lung carcinoma.